NC-004

NC-004 is a multi-track therapeutic candidate developed by NodCure, targeting metabolic and inflammatory pathways. It is being developed across three distinct categories: as a pharmaceutical for Metabolic-associated Steatohepatitis (MASH), as a health functional food for human obesity, and as a marketed product for animal healthcare (specifically canine obesity). While specific molecular targets are not explicitly disclosed in pipeline documentation, the developer's name and focus suggest the candidate likely modulates the Nucleotide-binding oligomerization domain (NOD) signaling pathway, which plays a critical role in innate immunity and metabolic regulation. In the human health sector, it is currently in Phase 1 clinical trials for obesity as a functional food, while the veterinary version is already approved and marketed.